.png)
ANGLE PLC's (LON:AGL, OTCQX:ANPCY) Andrew Newland talks to Proactive's Katie Pilbeam after announcing the completion of their submission to the FDA for its Parsortix PC1 liquid biopsy for use in women with metastatic breast cancer (MBC).
Newland calls the announcement 'a massive day' after five years' work, including over 400 technical reports and documents and the results from 15,000 samples, have now been submitted to the FDA.
He goes on to explain that the process could take six months to complete but alludes to similar companies who have completed a similar trajectory who 'have achieved investor valuations of multiple billions of dollars' as a consequence.
